Literature DB >> 27798731

Impact of combined lipid lowering and blood pressure control on coronary plaque: myocardial ischemia treated by percutaneous coronary intervention and plaque regression by lipid lowering and blood pressure controlling assessed by intravascular ultrasonography (MILLION) study.

Masa-Aki Kawashiri1, Kenji Sakata1, Kenshi Hayashi1, Tadatsugu Gamou1, Honin Kanaya2, Kenji Miwa2, Kosei Ueda3, Toshinori Higashikata3, Sumio Mizuno4, Ichiro Michishita5, Masanobu Namura6, Yutaka Nitta7, Shoji Katsuda7, Kazuyasu Okeie8, Hiroaki Hirase9, Hayato Tada1, Katsuharu Uchiyama1, Tetsuo Konno1, Hidekazu Ino3, Keisuke Nagase10, Masakazu Yamagishi11.   

Abstract

The aim of the study was to elucidate the aggressive reduction of both low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) reduced coronary atherosclerotic plaque volume compared with a standard treatment of LDL-C and BP in Japanese patients with coronary artery disease (CAD). This study is a prospective, randomized, and open-labelled with a blind-endpoint evaluation study. A total of 97 patients (81 men, mean age 62.0 ± 9.6) with CAD undergoing intravascular ultrasonography (IVUS)-guided percutaneous coronary intervention (PCI) were randomized, and 68 patients had IVUS examinations at baseline and at 18-24 months follow-up. Patients were randomly assigned to standard or aggressive strategies targeting LDL-C and a BP of 100 mg/dL and 140/90 mmHg vs. 70 mg/dL and 120/70 mmHg, respectively. The primary endpoint was the percent change in coronary plaque volume. Both standard and aggressive strategies succeeded to achieve target levels of LDL-C and BP; 74.9 ± 14.7 vs. 63.7 ± 11.9 mg/dL (NS) and 124.1 ± 9.4/75.8 ± 7.7 vs. 113.6 ± 9.6/65.8 ± 9.4 mmHg (systolic BP; NS, diastolic BP; p < 0.05), respectively. Both groups showed a significant reduction in the coronary plaque volume of -9.4 ± 10.7% and -8.7 ± 8.6% (NS) in standard and aggressive therapies, respectively. Both standard and aggressive intervention significantly regressed coronary plaque volume by the same degree, suggesting the importance of simultaneous reductions of LDL-C and BP for prevention of CAD.

Entities:  

Keywords:  Amlodipine; Atorvastatin; Coronary plaque volume; Intravascular ultrasound

Mesh:

Substances:

Year:  2016        PMID: 27798731     DOI: 10.1007/s00380-016-0910-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  26 in total

Review 1.  Optimizing LDL-C lowering with statins.

Authors:  James M McKenney
Journal:  Am J Ther       Date:  2004 Jan-Feb       Impact factor: 2.688

2.  Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study.

Authors:  Tomotaka Dohi; Katsumi Miyauchi; Shinya Okazaki; Takayuki Yokoyama; Naotake Yanagisawa; Hiroshi Tamura; Takahiko Kojima; Ken Yokoyama; Takeshi Kurata; Hiroyuki Daida
Journal:  Atherosclerosis       Date:  2009-12-04       Impact factor: 5.162

3.  Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.

Authors:  Atsushi Hirayama; Satoshi Saito; Yasunori Ueda; Tadateru Takayama; Junko Honye; Sei Komatsu; Osamu Yamaguchi; Yuxin Li; Junji Yajima; Shinsuke Nanto; Kenji Takazawa; Kazuhisa Kodama
Journal:  Circ J       Date:  2011-04-19       Impact factor: 2.993

4.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.

Authors:  Emmanuelle Vidal-Petiot; Ian Ford; Nicola Greenlaw; Roberto Ferrari; Kim M Fox; Jean-Claude Tardif; Michal Tendera; Luigi Tavazzi; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Lancet       Date:  2016-08-30       Impact factor: 79.321

5.  Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).

Authors:  Takahiko Kojima; Katsumi Miyauchi; Takayuki Yokoyama; Ken Yokoyama; Takeshi Kurata; Satoru Suwa; Masaki Kawamura; Hiroshi Tamura; Shinya Okazaki; Kenji Inoue; Yasumasa Fujiwara; Masataka Sumiyoshi; Kosei Tanimoto; Yuji Nakazato; Shinichiro Yamagami; Takafumi Hiro; Nobuyuki Komiyama; Hiroyuki Daida
Journal:  Circ J       Date:  2011-04-07       Impact factor: 2.993

6.  Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.

Authors:  Shinya Okazaki; Takayuki Yokoyama; Katsumi Miyauchi; Kazunori Shimada; Takeshi Kurata; Hitoshi Sato; Hiroyuki Daida
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

7.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

8.  Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.

Authors:  Masa-Aki Kawashiri; Kenji Sakata; Tadatsugu Gamou; Honin Kanaya; Kenji Miwa; Kosei Ueda; Toshinori Higashikata; Sumio Mizuno; Ichiro Michishita; Masanobu Namura; Yutaka Nitta; Shoji Katsuda; Kazuyasu Okeie; Hiroaki Hirase; Hayato Tada; Katsuharu Uchiyama; Tetsuo Konno; Kenshi Hayashi; Hidekazu Ino; Keisuke Nagase; Mitsuyasu Terashima; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2014-06-04       Impact factor: 2.037

9.  Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries.

Authors:  Clemens von Birgelen; Marc Hartmann; Gary S Mintz; K Gert van Houwelingen; Nadine Deppermann; Axel Schmermund; Dirk Böse; Holger Eggebrecht; Till Neumann; Mario Gössl; Heinrich Wieneke; Raimund Erbel
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

10.  Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.

Authors:  Paul N Hopkins; Joep Defesche; Sigrid W Fouchier; Eric Bruckert; Gérald Luc; Bertrand Cariou; Barbara Sjouke; Trond P Leren; Mariko Harada-Shiba; Hiroshi Mabuchi; Jean-Pierre Rabès; Alain Carrié; Charles van Heyningen; Valérie Carreau; Michel Farnier; Yee P Teoh; Mafalda Bourbon; Masa-Aki Kawashiri; Atsushi Nohara; Handrean Soran; A David Marais; Hayato Tada; Marianne Abifadel; Catherine Boileau; Bernard Chanu; Shoji Katsuda; Ichiro Kishimoto; Gilles Lambert; Hisashi Makino; Yoshihiro Miyamoto; Matthieu Pichelin; Kunimasa Yagi; Masakazu Yamagishi; Yassine Zair; Scott Mellis; George D Yancopoulos; Neil Stahl; Johanna Mendoza; Yunling Du; Sara Hamon; Michel Krempf; Gary D Swergold
Journal:  Circ Cardiovasc Genet       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.